Moderna has marked a significant milestone in the UK pharmaceuticals landscape by launching a £150m manufacturing and research facility in Oxfordshire. The ribbon-cutting ceremony, attended by Moderna’s chief executive Stéphane
NHS5- Page
164Articles
NHS staff outperformed government expectations last year, delivering a sharp improvement in productivity and offering a timely win for Chancellor Rachel Reeves ahead of the crucial autumn Budget. For the
Recent public announcements of cancer diagnoses by high-profile figures have inadvertently contributed to significant delays in the National Health Service’s cancer referral process, a senior coroner has observed. Samantha Goward,
Bristol Myers Squibb BMS has issued a pointed demand for the NHS to fund a greater share of pharmaceutical innovation calling for the UK to pay what it describes as
The National Health Service is making a significant stride towards modernising diagnostics with the introduction of a cloud-based screening platform designed to accelerate the identification of chronic diseases. With an
The battle between the NHS and pharmaceutical giants is reaching boiling point as accusations fly over the UK’s approach to funding modern medicines. A fresh row has ignited during President
Britain’s pharmaceutical sector has been thrust into sharp focus as the government pledges urgent action to resolve a standoff with multinational drug companies. In the aftermath of several high-profile withdrawals
Merck, the renowned US pharmaceuticals giant known as MSD across Europe, has abandoned plans for a £1 billion research centre in London—a significant blow for the UK life sciences sector.
The health secretary Wes Streeting has issued a direct appeal to newly qualified doctors, urging them to refrain from joining strike action orchestrated by the British Medical Association. Writing in
The United Kingdom stands on the threshold of a radical transformation in obesity treatment, as Eli Lilly prepares to introduce a daily weight-loss pill, Orforglipron, in 2026, once regulatory approval
New data from NHS England reveals that specialist artificial intelligence (AI) technology is transforming outcomes for stroke patients, tripling the likelihood of making a full recovery in some cases. Since
Britain faces a growing crisis in its life sciences sector as a senior executive at Novartis has declared the UK “uninvestable” owing to stringent and outdated drug pricing policies. Johan
Eli Lilly, one of the world’s largest pharmaceutical companies, has temporarily halted orders of its highly sought-after weight-loss injection, Mounjaro, to the UK. This move comes as the market braces
Wes Streeting, the new health secretary, has escalated his confrontation with leading pharmaceutical firms over the soaring cost of medicines and its impact on the UK’s broader life sciences sector.
Weight loss medications, specifically GLP1 agonists like Ozempic Wegovy and Mounjaro, are redefining the landscape of healthcare in Britain, with new research signposting not only longer lives for millions but
Labour is preparing to reignite public private partnerships (PPPs) as a solution for delivering new neighbourhood health centres central to its ambitious 10year NHS plan. Ministers are set to make
